Clinical Trials

List clinical trials by disease

The results of your search are listed below. To view the details of a trial or study, click on the "see details >" link. Or start a new search.

Searched for: Lung Cancer. 30 results shown below.

Radiation Therapy, Cisplatin, and Etoposide in Treating Patients With Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery

[Complete title: A Phase I dose-intensification study using radiation therapy and concurrent cisplatin and etoposide for patients with inoperable non-small cell lung cancer]
Principal Investigator: Shilpen Patel, MD
Study Number: 7506
Phase: I

Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Previously Treated Advanced Non-Small Cell Lung Cancer

[Complete title: A Phase II Study of Weekly ABRAXANE® for Patients with Advanced NSCLC with EGFR Mutations or with Durable Response to an EGFR Tyrosine Kinase Inhibitor following Front-Line Therapy with EGFR Tyrosine Kinase Inhibitors]
Principal Investigator: Christina Baik
Study Number: 7755
Phase: II

SPECT/CT in Measuring Lung Function in Patients With Lung Cancer Undergoing Radiation Therapy

[Complete title: Pulmonary Functional Imaging for Radiation Treatment Planning for Lung Cancer]
Principal Investigator: Jing Zeng
Study Number: 8180
Phase: Pilot

Proton Beam Radiation Therapy in Treating Patients With Recurrent Thoracic Cancer Who Have Received Prior Radiation Therapy

[Complete title: Definitive Re-Irradiation with Proton Beam Radiotherapy for Patients with Recurrent Thoracic Cancers]
Principal Investigator: Jing Zeng
Study Number: 9148
Phase: Pilot

Genetically Modified T Cells in Treating Patients With Stage III-IV Non-small Cell Lung Cancer or Mesothelioma

[Complete title: Phase I/II study in WT1-expressing non-small cell lung cancer and mesothelioma, comparing cellular adoptive immunotherapy with polyclonal autologous central memory to naïve CD8+ T cells that have been transduced to express a WT1-specific T cell receptor]
Principal Investigator: Sylvia Lee, MD
Study Number: 2727.00
Phase: I/II

Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)

[Complete title: Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)]
Principal Investigator: Rafael Santana-Davila
Study Number: A081105
Phase: III

Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)

[Complete title: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)]
Principal Investigator: Rafael Santana-Davila
Study Number: A151216
Phase: NA

Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)

[Complete title: A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein]
Principal Investigator: Rafael Santana-Davila
Study Number: E4512
Phase: III

Lung-MAP: S1400 Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IIIB-IV Squamous Cell Lung Cancer

[Complete title: Phase II/III Biomarker-Driven Master Protocol for Second Line Therapy of Squamous Cell Lung Cancer (Lung-Map)]
Principal Investigator: Christina Baik
Study Number: S1400
Phase: II/III

A Phase II Study of the Selective BRAF Kinase Inhibitor GSK2118436 in Subjects With Advanced Non-small Cell Lung Cancer and BRAF Mutations

[Complete title: A Phase II Study of the Selective BRAF Kinase Inhibitor GSK2118436 in Subjects with Advanced Non-Small Cell Lung Cancer and BRAF Mutations]
Principal Investigator: Christina Baik
Study Number: 20111838
Phase: II

Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012)

[Complete title: A Multi-arm Phase I Study of BMS-936558 in Combination with Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, or Carboplatin/Paclitaxel in Subjects with Treatment-Naive Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC)]
Principal Investigator: Laura Chow
Study Number: 20120011
Phase: I

Study to Evaluate Safety, Pharmacokinetics, and Efficacy of Rociletinib (CO-1686) in Previously Treated Mutant Epidermal Growth Factor Receptor (EGFR) in Non-Small Cell Lung Cancer (NSCLC) Patients

[Complete title: A Phase 1/2, Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of Oral CO-1686 in Patients with Previously Treated Mutant EGFR Non-Small Cell Lung Cancer (NSCLC)]
Principal Investigator: Christina Baik
Study Number: 20120636
Phase: I/II

AZD8186 First Time In Patient Ascending Dose Study

[Complete title: A Phase 1, Open-label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of AZ8186 in Patients with Advanced Castrate-resistant Prostate Cancer (CRPC), Squamoous Non-Small Cell Lung Cancer (sqNSCLC), Triple Negative Breast Cancer (TNBC) and Patients with Known PTEN-Deficient Advance Solid Malignancies, with Expansion to Assess the Pharmacodynamic Activity of AZ8186 with Prospectively-validated PTEN-deficient Tumors]
Principal Investigator: Tia Higano, MD
Study Number: 20131275
Phase: I

A Phase 2 Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) in Patients With PD-L1 Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer - "BIRCH"

[Complete title: A Phase II, Multicenter, Single-Arm study of MPDL3280A in Patients with PD-L1-Positive Locally Advanced or Metastatic Non-Small Cell lung Cancer]
Principal Investigator: Laura Chow
Study Number: 20131756
Phase: II

A Phase 1b Study of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Non-small Cell Lung Cancer (D4190C00006)

[Complete title: A Phase 1b Open-label Study to Evaluate the Safety and Tolerability of MEDI4736, in Combination with Tremelimumab in Subjects with Advanced Non-Small Cell Lung Cancer]
Principal Investigator: Sylvia Lee, MD
Study Number: 20131955
Phase: I/II

MSB0010718C in Solid Tumors

[Complete title: A Phase I, Open-label, Multiple-ascending Dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of MSB0010718C in Subjects With Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications]
Principal Investigator: Nora Disis, MD
Study Number: 20132079
Phase: I

Phase 2 Study of Alisertib (MLN8237) in Combination With Paclitaxel Versus Placebo in Combination With Paclitaxel as Second Line Therapy for Small Cell Lung Cancer (SCLC)

[Complete title: A Randomized, Double-blind, Placebo-controlled, Phase 2 Clinical Trial of Alisertib (MLN8237) in Combination With Paclitaxel Versus Placebo in Combination With Paclitaxel as Second Line Therapy for Small Cell Lung Cancer (SCLC)]
Principal Investigator: Christina Baik
Study Number: 20140088
Phase: II

MEDI4736 (Anti PD-L1) Combined With Gefitinib in Subjects With Non-Small Cell Lung Cancer(NSCLC)

[Complete title: A Phase I, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity of gefitinib in Combination with MEDI4736 (anti PD-L1) in Subjects with Non-Small Cell Lung Cancer(NSCLC)]
Principal Investigator: Laura Chow
Study Number: 20140532
Phase: I

Ruxolitinib in Combination With Pemetrexed/Cisplatin in Non Small Cell Lung Cancer

[Complete title: A Randomized, Double-Blind Phase 2 Study of Ruxolitinib or Placebo in Combination With Pemetrexed/Cisplatin and Pemetrexed Maintenance for Initial Treatment of Subjects With Nonsquamous Non–Small Cell Lung Cancer That Is Stage IIIB With Pleural/Pericardial Effusion, Stage IV, or Recurrent.]
Principal Investigator: Christina Baik
Study Number: 20140650
Phase: II

ME-344 Given in Combination With Hycamtin® in Patients With Solid Tumors

[Complete title: A Phase Ib Open Label Study of the Safety and Tolerability of ME-344 Given in Combination with Topotecan (Hycamtin®) in Patients with Solid Tumors]
Principal Investigator: Barbara Ann Goff, MD
Study Number: 20140982
Phase: I

A Study Of PF-06664178 In Patients With Advanced Solid Tumors

[Complete title: A Phase 1, Dose Escalation Study of PF-06664178 in Patients with Locally Advanced or Metastatic Solid Tumors]
Principal Investigator: Keith Eaton, MD, PhD
Study Number: 20141074
Phase: I

Selinexor Treatment of Advanced Relapsed/Refractory Squamous Cell Carcinomas (STARRS)

[Complete title: A Phase 2, Open-label Study of the Safety and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) in Patients with Advanced Squamous Cell Carcinoma of Head and Neck, Lung, or Esophagus]
Principal Investigator: Tina Rodriguez
Study Number: 20141119
Phase: II

A Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy or Immunotherapy in Participants With Lung Cancer (MK-3475-021/KEYNOTE-021)

[Complete title: A Phase I/II Study of MK-3475 (SCH900475) in Combination with Chemotherapy or Immunotherapy in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Carcinoma]
Principal Investigator: Renato Martins, MD, MPH
Study Number: 20141233
Phase: I/II

A Study of MPDL3280A in Combination With INCB024360 in Subjects With Previously Treated Stage IIIB or Stage IV Non-Small Cell Lung Cancer

[Complete title: A Phase 1 Study of MPDL3280A in Combination With INCB024360 in Subjects With Previously Treated Stage IIIB, Stage IV, or Recurrent Non–Small Cell Lung Cancer]
Principal Investigator: Laura Chow
Study Number: 20141860
Phase: I

TIGER-1: Safety and Efficacy Study of Rociletinib (CO-1686) or Erlotinib in Patients With EGFR Mutant NSCLC Who Have Not Had Any Previous EGFR Directed Therapy

[Complete title: TIGER 1: A Randomized, Open-Label, Phase II Study of CO-1686 or Erlotinib as First-Line Treatment of Patients with EGFR-Mutant Advanced Non-Small Cell Lung Cancer (NSCLC)]
Principal Investigator: Christina Baik
Study Number: 20142085
Phase: II

A Study of Trastuzumab Emtansine in Patients With HER2 IHC-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer

[Complete title: A Phase II, Multicenter, Single-Arm Study of Trastuzumab Emtansine in Patients with HER2 IHC-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Received at Least One Prior Chemotherapy Regimen]
Principal Investigator: Christina Baik
Study Number: 20142268
Phase: II

Safety Study of Nivolumab With Nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, Nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or Nab-Paclitaxel in Recurrent Metastatic Breast Cancer

[Complete title: A Phase 1, Open-label, Multicenter, Safety Study of Nivolumab (BMS-936558) in Combination with nab-Paclitaxel plus or minus Gemcitabine in Pancreatic Cancer, nab-Paclitaxel/Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or nab-Paclitaxel in Recurrent Metastatic Breast Cancer]
Principal Investigator: Gabriela Chiorean
Study Number: 20150466
Phase: I

Study For Patients With NSCLC EGFR Mutations (Del 19 or L858R +/- T790M)

[Complete title: Phase 1/2 Open-Label Study of PF-06747775 (Epidermal Growth Factor Receptor T790M Inhibitor) in Patients with Advanced Epidermal Growth Factor Receptor Mutant (DEL 19 OR L858R +/- T790M) Non-Small Cell Lung Cancer]
Principal Investigator: Renato Martins, MD, MPH
Study Number: 20150645
Phase: I/II

A Phase 1 Safety Study of Intradermal ID-LV305 in Patients With Locally Advanced, Relapsed or Metastatic Cancer Expressing NY-ESO-1

[Complete title: A Phase 1, Open-Label Clinical Trial Evaluating the Safety, Tolerability and Immunogenicity of Intradermally Administered ID-LV305 in Patients with Locally Advanced, Relapsed or Metastatic Cancer Expressing NY-ESO-1 20140453]
Principal Investigator: Seth Pollack
Study Number: 9079
Phase: I

A Phase 1b Safety Study of CMB305 (Sequentially Administered LV305 and G305) in Patients With Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1

[Complete title: A Phase 1b Study Evaluating the Safety, Tolerability and Immunogenicity of CMB305 (Sequentially Administered LV305 and G305) in Patients with Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1]
Principal Investigator: Seth Pollack
Study Number: 9290
Phase: I

Select a disease from the list below:

Limit results to studies enrolling:

OR

Search by Keyword, Investigator Name or Study ID#:

Limit results to studies enrolling:

OR

View all studies

Limit results to studies enrolling:

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Please remember:

  • Talk to your health care providers first before making decisions about your health care.
  • Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.

Subscribe to an RSS feed of all trials